{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0079556\nAge: 48\nGender: Male\nSample ID: P-0079556-T02-IM7\nGene Panel: IMPACT505\nCancer Type: Rectal Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nBRAF c.1799T>A (p.V600E) - in 75.00% of 491 reads\nERCC2 c.1406A>G (p.K469R) - in 16.00% of 947 reads\nINPP4B c.1154T>G (p.L385R) - in 36.00% of 357 reads\nPNRC1 c.65G>C (p.G22A) - in 27.00% of 620 reads\nPTPRT c.2020_2021delinsAT (p.P674I) - in 15.00% of 684 reads\nRHEB c.173T>A (p.L58H) - in 28.00% of 570 reads\nSDHA c.410A>G (p.D137G) - in 27.00% of 364 reads\nSMAD4 c.1487G>A (p.R496H) - in 45.00% of 293 reads\nTP53 c.646G>A (p.V216M) - in 67.00% of 463 reads\nCNA Data:\nPTEN - Homozygous Deletion\nKDM6A - Homozygous Deletion\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Rectal Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Pembrolizumab\",\n    \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment\",\n    \"Genomic Features\": \"MSI-high (microsatellite instability-high)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf\"\n  }\n}"
}